SZU305
SZU305 is a RAD51 PROTAC degrader, with DC50 values of 307.45 nM and 84.19 nM in SK-HEP-1 and Huh-7 cells, respectively. SZU305 inhibits DNA damage repair, induces cell cycle arrest and apoptosis. SZU305 moderately reduces the protein levels of IKZF1 and IKZF3 at high concentrations. SZU305 can be used in studies related to hepatocellular carcinoma.
(Pink: RAD51 ligand (HY-167881); Blue: Cereblon ligand (HY-W087383); Black: linker).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C32H28Cl3FN6O6
- Masse moléculaire:717.96
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform PROTACs
MoreVoir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
Description
IC50 & Target
[1]|
Cereblon |
IKZF1 |
IKZF3 |
In Vitro
SZU305 (0.3-3 μM; 48 h) potently induces nearly complete degradation of RAD51 in human hepatocellular carcinoma cells SK-HEP-1 following treatment with 3 μM for 48 h[1].
Removal of SZU305 (3 μM; 48 h) causes a gradual recovery of RAD51 protein levels within 24 h in human hepatocellular carcinoma SK-HEP-1 cells, indicating that the turnover rate of RAD51 is relatively slow[1].
SZU305 (3 μM; 48 h) induces RAD51 degradation in the human hepatocellular carcinoma cell line SK-HEP-1 via a CRBN- and proteasome-dependent mechanism, and this degradation process relies on ubiquitin-like modification and competitive binding to the catalytic site of RAD51[1].
SZU305 (0.5-10 μM; 72 h) exerts concentration-dependent antiproliferative activity against human hepatocellular carcinoma cell line SK-HEP-1 after 72 h of treatment[1].
SZU305 (1.25-10 μM; 12-14 days) potently inhibits colony formation of human hepatocellular carcinoma cell line SK-HEP-1[1].
SZU305 (5-10 μM; 72 h) induces dose-dependent G2/M cell cycle arrest in human hepatocellular carcinoma SK-HEP-1 cells following 72 h of treatment at concentrations of 5 μM and 10 μM[1].
Treatment with SZU305 (5-10 μM; 72 h) induces dose-dependent apoptosis in human hepatocellular carcinoma cell line SK-HEP-1[1].
SZU305 (3 μM; 48 h) selectively degrades the RAD51 protein in SK-HEP-1 human hepatocellular carcinoma cells, without significantly altering its mRNA level after 48 h of treatment at 3 μM, while regulating the expression of genes and proteins involved in DNA damage repair, apoptosis and stress response[1].
SZU305 (3 μM; 48 h) enhances DNA damage in SK-HEP-1 human hepatocellular carcinoma cells[1].
Treatment of DR-U2OS reporter cells with SZU305 for 48 h impairs their homologous recombination repair efficiency, but exerts no significant effect on non-homologous end joining in EJ5-U2OS reporter cells[1].
SZU305 enhances chromosome breakage in the human hepatocellular carcinoma cell line SK-HEP-1 when combined with 3 Gy IR, suggesting impaired DNA damage repair function[1].
SZU305 impairs the formation of γ-H2AX foci in the human hepatocellular carcinoma cell line SK-HEP-1, and this effect is enhanced when combined with VP16, CPT, sorafenib or IR, suggesting that it disrupts the DNA damage response[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SK-HEP-1 human liver cancer cells
-
Concentration:0.3 μM; 3 μM
-
Incubation Time:48 h
-
Result:Induced ~99% RAD51 degradation at 3 μM after 48 h.
-
Cell Line:SK-HEP-1 human liver cancer cells
-
Concentration:3 μM
-
Incubation Time:48 h (15b treatment); 0, 4, 8, 12, 24 h (drug-free recovery)
-
Result:Allowed RAD51 protein expression to gradually recover within 24 h after removal.
-
Cell Line:SK-HEP-1 human liver cancer cells
-
Concentration:3 μM (15b treatment); MG132, MLN4924, pomalidomide, RI-1, 5a (pretreatment); siCRBN (pretreatment)
-
Incubation Time:48 h (15b treatment); 2 h (MG132, MLN4924, pomalidomide, RI-1, 5a pretreatment); 48 h (siCRBN pretreatment)
-
Result:Had RAD51 degradation completely abolished by co-incubation with MG132.
Showed RAD51 degradation prevented or diminished by MLN4924, pomalidomide, RI-1, 5a, and siCRBN.
-
Cell Line:SK-HEP-1 human liver cancer cells
-
Concentration:0.5, 1, 2.5, 5, 10 μM
-
Incubation Time:72 h
-
Result:Inhibited SK-HEP-1 cell proliferation in a concentration-dependent manner, with reduced cell viability observed at all tested concentrations.
-
Cell Line:SK-HEP-1 human liver cancer cells
-
Concentration:1.25, 2.5, 5 and 10 μM
-
Incubation Time:12-14 days
-
Result:Suppressed colony formation more effectively than RI-1 at equivalent concentrations.
-
Cell Line:SK-HEP-1 human liver cancer cells
-
Concentration:5 μM; 10 μM
-
Incubation Time:72 h
-
Result:Induced dose-dependent cell cycle arrest at the G2/M phase, with G1 phase population reduced from 80.15% (control) to 50.07% (5 μM) and 46.36% (10 μM), while G2/M phase population increased from 12.49% (control) to 34.63% (5 μM) and 38.42% (10 μM).
-
Cell Line:SK-HEP-1 human liver cancer cells
-
Concentration:5 μM; 10 μM
-
Incubation Time:72 h
-
Result:Induced dose-dependent apoptosis, with up to ~23% apoptotic cells observed at 10 μM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (4-6 weeks old)[1]
-
Dosage:15 mg/kg
-
Administration:i.v.; once every other day, 3 doses total
-
Result:Suppressed tumor growth with a T/C ratio of 75.6%.
Combined with sorafenib, achieved a T/C ratio of 16.7%.
Combined with 3 Gy irradiation, achieved a T/C ratio of 2.3%.
Caused no body weight loss, indicating low toxicity.
Induced RAD51 degradation in tumor tissue.
Reduced RAD51 and Ki67 expression in tumor tissue.
Elevated cleaved caspase-3 levels in tumor tissue, with greater effects seen in combination with sorafenib or irradiation.
Chemical Information
-
Masse moléculaire 717.96
-
Formule C32H28Cl3FN6O6
-
SMILES
O=C1N(C(C2=C1C=C(C(N3CC(CC3)CN4CCN(C5=C(C(N(C5=O)C6=CC=C(C(Cl)=C6)Cl)=O)Cl)CC4)=C2)F)=O)C7C(NC(CC7)=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)